When was ISA Pharmaceuticals founded?

ISA Pharmaceuticals was founded in 2004 and raised its 1st funding round 9 years after it was founded.

Where is ISA Pharmaceuticals located?

ISA Pharmaceuticals is headquartered in Leiden, Netherlands.

Who is the current CEO of ISA Pharmaceuticals?

Ronald Loggers of ISA Pharmaceuticals.

How many employees does ISA Pharmaceuticals have?

As of May 31, 2026, the latest employee count at ISA Pharmaceuticals is 5.

Is ISA Pharmaceuticals a funded company?

ISA Pharmaceuticals is a funded company, having raised a total of $40.6M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 07, 2013.

When was the latest funding round of ISA Pharmaceuticals?

ISA Pharmaceuticals' latest funding was a $***** Series B round on Jul 13, 2021, with participation from 2 investors. Its primary sector is Infectious Diseases. In Netherlands, the Infectious Diseases sector has seen $65.6M in funding in 2026 to date.

Where does ISA Pharmaceuticals rank among its competitors?

ISA Pharmaceuticals ranks 1026th amongst 3593 active competitors, of which 1186 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of ISA Pharmaceuticals?

ISA Pharmaceuticals' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

ISA Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutic vaccines for cancer and infectious diseases. The drug pipeline includes ISA101 which consists of13 synthetic long peptides derived from the E6 and E7 oncogenic proteins of the HPV 16 virus for the treatment of human papillomavirus type 16 induced diseases, including cervical cancer, most anogenital premalignant and malignant lesions, and head and neck cancer, and others.

Key Metrics

Founded Year

2004

Location

Leiden, Netherlands

Stage

Series B

Total Funding

$40.6M in 4 rounds

Latest Funding Round

Series B, Jul 13, 2021, $*****

Investors

Regeneron Pharmaceuticals & 7 more

Ranked

1026^th among 3593 active competitors

Employee Count

5 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3367 more

View ISA Pharmaceuticals' full profile

ISA Pharmaceuticals has raised a total funding of $40.6M over 4 rounds. Its first funding round was on Jan 07, 2013. Its latest funding round was a Series B round on Jul 13, 2021 for $*****. 2 investors participated in its latest round. ISA Pharmaceuticals has 8 institutional investors.

Here is the list of recent funding rounds of ISA Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 13, 2021	2241304	Series B	1897344	4062115	1705383	9296280
Oct 14, 2019	5503218	Conventional Debt	4409993	5476964	1541799	European Investment Bank
Dec 01, 2017	7496230	Grant (prize money)	7541006	1530329	8955077	Europa

Access funding benchmarks and valuations. Sign up today!

View details of ISA Pharmaceuticals's funding rounds and investors

The founders of ISA Pharmaceuticals is Karl Rothweiler.

Here are the details of ISA Pharmaceuticals' key team members:

Karl Rothweiler: Founder, Founding Investor, Member of the Supervisory Board of ISA Pharmaceuticals and founder of 2 other companies, InteRNA Technologies and Sapreme Technologies.
Ronald Loggers: CEO of ISA Pharmaceuticals.

View details of ISA Pharmaceuticals's Founder profiles and Board Members

ISA Pharmaceuticals' employee count trend

ISA Pharmaceuticals has 5 employees as of May 26. Here is ISA Pharmaceuticals's employee count trend over the years:

Employee count trend for ISA Pharmaceuticals

Uncover ISA Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ISA Pharmaceuticals include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of ISA Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, Khosla Ventures & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1026th	ISA Pharmaceuticals 2004, Leiden (Netherlands), Series B	Developer of therapeutic vaccines for cancer and infectious diseases	$40.6M	European Investment Bank, Regeneron Pharmaceuticals ... & 6 others	41/100